此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

DN-tTIS for Post-Stroke Motor Recovery

2026年11月16日 更新者:Tang Zhouping、Tongji Hospital

Safety and Efficacy of Non-invasive Temporal Interference Electrical Stimulation of the Cerebellar Dentate Nucleus for Upper Limb Motor Recovery in Chronic Stroke: A Preliminary Study

This study aims to explore a new, non-invasive treatment to help patients recover upper limb motor function after a stroke. Many stroke survivors experience long-term movement difficulties, and standard physical therapies may not always be effective, especially for those with severe motor impairments. Previous research suggests that stimulating a specific deep brain region called the cerebellar dentate nucleus can promote motor recovery, but traditional methods require invasive surgery.

In this study, researchers will investigate a novel technology called Temporal Interference (TI) electrical stimulation. TI allows researchers to safely and painlessly stimulate deep brain areas from the scalp without any surgery or implanted electrodes. The research team will enroll 10 patients who experienced a stroke 1 to 3 years ago and still have moderate to severe upper limb weakness. Participants will receive TI stimulation therapy 5 times a week for 4 weeks. Before, during, and after the treatment period, the researchers will use clinical physical assessments, brain imaging (fMRI), and non-invasive brain monitoring (EEG and fNIRS) to evaluate whether this treatment is safe, feasible, and effective for improving upper limb movement in chronic stroke survivors.

研究概览

地位

尚未招聘

条件

研究类型

介入性

注册 (估计的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • * Meets the diagnostic criteria for "stroke" in the "Key Points for Diagnosis of Major Cerebrovascular Diseases in China 2019", and confirmed by cranial CT or MRI.

    • First-ever stroke, with a disease duration of 1 year to 3 years (inclusive).
    • Age between 18 and 70 years old (inclusive).
    • Ischemic stroke in the territory of the unilateral middle cerebral artery, without affecting the cerebellum, thalamus, and brainstem.
    • Stable medical and neurological conditions, as determined by the investigator based on medical history, physical, and neurological examinations.
    • Residual moderate to severe unilateral upper limb hemiplegia, defined as an Upper Extremity Fugl-Meyer Assessment (FMA-UE) score of ≤ 50 on the affected side.
    • A score of ≥ 1 in at least one of the following FMA-UE sub-items: elbow flexion, elbow extension, or finger grasp.
    • Modified Rankin Scale (mRS) score < 4.
    • No spasticity or moderate spasticity in the affected limb, defined as a Modified Ashworth Scale (MAS) score < 4 in any region of the affected limb (shoulder internal rotators and adductors, elbow flexors, wrist flexors, or finger flexors).
    • Mini-Mental State Examination (MMSE) score ≥ 24.

Exclusion Criteria:

  • Primary hemorrhagic stroke or severe hemorrhagic transformation.

    • Presence of any other progressive neurological or somatic diseases impairing the target limb function, other than stroke.
    • Moderate to severe unilateral spatial neglect or anosognosia involving the affected side of the body.
    • Presence of any other neurological diseases that may compromise the safety of study participation, including central nervous system vasculitis, intracranial tumors, intracranial aneurysms, multiple sclerosis, or arteriovenous malformations.
    • Pain in the affected limb, defined as a pain score of ≥ 5 on the 0-10 Numeric Rating Scale (NRS).
    • Severe sensory impairment, demonstrated by a score of 2 on the National Institutes of Health Stroke Scale (NIHSS) sensory item (Item 8).
    • Occurrence of seizures since the stroke, regardless of the use of antiepileptic drugs.
    • Diagnosis of underlying seizure disorder or epilepsy.
    • Changed the dose of oral anti-spasticity medications within 2 weeks prior to study consent, or received botulinum toxin injections in the affected arm within 4 months prior to study consent, and/or plans to start anti-spasticity medications or botulinum toxin injections during the study follow-up period.
    • Presence of major active psychiatric illnesses that may interfere with treatment, such as psychotic disorders or severe personality disorders.
    • Untreated or inadequately treated depression, defined as a Beck Depression Inventory-II (BDI-II) score of ≥ 20 at enrollment.
    • Diagnosis of dementia.
    • Chronic uncontrolled hypertension, or a history of severe and uncontrolled cardiovascular disease.
    • Contraindications to Magnetic Resonance Imaging (MRI), such as body weight incompatible with the scanner, or implanted metallic/electronic devices (pacemakers, defibrillators, spinal cord stimulators, etc.).
    • Presence of severe and poorly controlled medical conditions which, in the opinion of the Principal Investigator (PI), would pose an expected risk higher than that of the general stroke population.
    • Currently participating in another device, biologic, or drug study, or has not completed one within 30 days prior to consenting to this study.
    • Pregnancy (women of childbearing potential must use acceptable methods of contraception).
    • History of hemicraniectomy.
    • History of cerebrovascular stent implantation.
    • Presence of significant chronic small vessel ischemic disease, vertebrobasilar vascular disease, and/or any other structural abnormalities in the cerebellum, cerebellar peduncles, or brainstem.
    • Any other condition that, in the opinion of the investigator, would significantly increase the risk of interfering with study compliance, safety, or outcomes.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental: tTIS Intervention Group

All enrolled patients with chronic stroke will be assigned to this single arm to receive non-invasive temporal interference electrical stimulation (tTIS) therapy.

Patients will receive non-invasive temporal interference electrical stimulation targeting the contralateral cerebellar dentate nucleus. The stimulation is delivered with a total current of 6 mA. The treatment is administered 5 times a week for 4 consecutive weeks. Each treatment day includes two 40-minute tTIS sessions.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The safety of the tTIS intervention
大体时间:Up to 4 weeks(from baseline to the end of treatment)

Safety will be evaluated by monitoring the incidence of adverse events (AEs), serious adverse events (SAEs), serious adverse device effects (SADEs), and unanticipated adverse device effects (UADEs) throughout the study period. An adverse event is defined as any untoward medical occurrence associated with the use of the intervention. A lower incidence (fewer participants experiencing AEs) indicates a better safety profile and therefore a better outcome.

Up to 4 weeks(from baseline to the end of treatment)

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in Upper Extremity Fugl-Meyer Assessment (FMA-UE) Score
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

Upper limb motor function was assessed using the Upper Extremity Subscale of the Fugl-Meyer Assessment (FMA-UE), which has a total score range of 0 to 66. In this scale, a higher score indicates better upper limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 66 representing normal motor function. Changes in the score reflect the degree of improvement in upper limb motor function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Action Research Arm Test (ARAT) Score
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

Upper limb functional limitation and dexterity were assessed using the Action Research Arm Test (ARAT), which has a total score range of 0 to 57. In this scale, a higher score indicates better arm motor function and therefore a better outcome, with 0 representing no movement possible and 57 representing normal performance. Changes in the score reflect the degree of improvement in upper limb function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Lower Extremity Fugl-Meyer Assessment (FMA-LE) Score
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

Lower limb motor function was assessed using the Lower Extremity Subscale of the Fugl-Meyer Assessment (FMA-LE), which has a total score range of 0 to 34. In this scale, a higher score indicates better lower limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 34 representing normal motor function. Changes in the score reflect the degree of improvement in lower limb motor function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Berg Balance Scale (BBS) Score
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

Static and dynamic balance abilities were assessed using the Berg Balance Scale (BBS), which has a total score range of 0 to 56. In this scale, a higher score indicates better balance function and therefore a better outcome, with 0 representing severely impaired balance and 56 representing excellent balance. Changes in the score reflect the degree of improvement in balance and fall risk reduction.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Modified Barthel Index (MBI)
大体时间:Baseline and Week 4

The patient's performance in activities of daily living was assessed using the Modified Barthel Index (MBI), which has a total score range of 0 to 100. In this scale, a higher score indicates a higher degree of independence in daily life and therefore a better outcome, with 0 representing complete dependence and 100 representing complete independence. Changes in the score reflect the degree of improvement in daily living abilities.

Baseline and Week 4
Change from baseline in Modified Ashworth Scale (MAS) Score
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

Muscle spasticity was assessed using the Modified Ashworth Scale (MAS), which has a total score range of 0 to 4 (scored as 0, 1, 1+, 2, 3, 4). In this scale, a higher score indicates greater severity of muscle spasticity and therefore a worse outcome, with 0 representing no increase in muscle tone and 4 representing the affected part being rigid in flexion or extension. Changes in the score reflect the degree of improvement in muscle spasticity.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Brunnstrom Recovery Stages
大体时间:Baseline, Week 1, Week 2, Week 3, and Week 4

The motor recovery process after stroke was assessed using the Brunnstrom Motor Recovery Stages, which classifies recovery into a range of Stage I to Stage VI (mapped to scores 1 to 6). In this scale, a higher stage indicates better voluntary motor control and therefore a better outcome, with Stage I representing flaccidity (no voluntary movement) and Stage VI representing near-normal joint movements. Changes in the stage reflect the progression of motor recovery.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Mini-Mental State Examination (MMSE) Score
大体时间:Baseline and Week 4

Cognitive function was assessed using the Mini-Mental State Examination (MMSE), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

Baseline and Week 4
Change from baseline in Montreal Cognitive Assessment (MoCA) Score
大体时间:Baseline and Week 4

Mild cognitive dysfunction was assessed using the Montreal Cognitive Assessment (MoCA), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

Baseline and Week 4
Change from baseline in Hamilton Depression Rating Scale (HAMD) Score
大体时间:Baseline and Week 4

The severity of depressive symptoms was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), which has a total score range of 0 to 52. In this scale, a higher score indicates greater severity of depression and therefore a worse outcome, with 0 representing no depression and 52 representing the most severe depression. Changes in the score reflect the degree of improvement in depressive symptoms.

Baseline and Week 4
Change from baseline in Hamilton Anxiety Rating Scale (HAMA) Score
大体时间:Baseline and Week 4

The severity of anxiety symptoms was assessed using the Hamilton Anxiety Rating Scale (HAMA), which has a total score range of 0 to 56. In this scale, a higher score indicates greater severity of anxiety and therefore a worse outcome, with 0 representing no anxiety and 56 representing the most severe anxiety. Changes in the score reflect the degree of improvement in anxiety symptoms.

Baseline and Week 4

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年1月15日

研究注册日期

首次提交

2026年11月15日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅